Antibody-drug conjugates (ADCs) represent a groundbreaking approach to cancer treatment. They involve combining monoclonal antibodies with chemotherapy drugs, enabling the precise targeting of cancer cells while minimizing damage to healthy tissues. Despite their considerable potential, the development of ADCs poses challenges such as conjugation efficiency, drug release at the target site, and side effect management.
This report will explore the recent advancements in ADC technology, delve into the components that influence ADC functionality, and propose strategies to address the pivotal challenges encountered during the development phase, including optimizing the antibody, improving payload conjugation and evaluating payload delivery.
Guest speaker
Dr. Zhicheng Dong
ACROBiosystems Product Manager
Topic:
Addressing Challenges in Antibody-Drug Conjugate Development
Speaker bio:
Clarence DEFFAUD holds a PhD in molecular and cellular biology from the Ecole Normale Supérieure de Lyon (ENS, INSERM U412 - LaboRetro). After his thesis, he founded IRESYS, a start-up specializing in drug discovery based on combinatorial screening of cell banks and filed a patent (PCT / FR2002 / 004124). In 2003, he joined HYBRIGENICS, a company specializing in protein-protein interactions, as "Yeast two Hybrid Service Manager" and participated in the realization of various scientific projects, including the creation of new expression banks. He also co-founded BIO-RD. Clarence DEFFAUD joined BIOTEM in 2005 as CEO/CSO. Since 2005, he has supervised more than 1000 projects, including the development of monoclonal antibodies for research, diagnostics and therapeutics.
Organizers
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.